Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Inventory (2019 - 2021)

VYNE Therapeutics' Inventory history spans 3 years, with the latest figure at $7.3 million for Q4 2021.

  • For Q4 2021, Inventory fell 1.53% year-over-year to $7.3 million; the TTM value through Dec 2021 reached $7.3 million, down 1.53%, while the annual FY2021 figure was $7.3 million, 1.53% down from the prior year.
  • Inventory reached $7.3 million in Q4 2021 per VYNE's latest filing, down from $8.1 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $8.3 million in Q2 2021 to a low of $1.4 million in Q4 2019.
  • Average Inventory over 3 years is $6.2 million, with a median of $7.3 million recorded in 2021.
  • Peak YoY movement for Inventory: soared 446.02% in 2020, then fell 1.53% in 2021.
  • A 3-year view of Inventory shows it stood at $1.4 million in 2019, then skyrocketed by 446.02% to $7.4 million in 2020, then fell by 1.53% to $7.3 million in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Inventory are $7.3 million (Q4 2021), $8.1 million (Q3 2021), and $8.3 million (Q2 2021).